Rate and predictors of loss to follow-up in HIV care in a low-resource setting: analyzing critical risk periods
Published in Biomedical Research
Why Do Some People Stop HIV Treatment? Understanding the Key Moments
In the global fight against HIV, keeping people engaged in their treatment is crucial. Even though many countries aim to meet ambitious HIV care goals by 2030, a significant challenge remains: helping those who start HIV treatment continue their care and keep their virus under control. A big part of this challenge is what’s known as "loss to follow-up" (LTFU).
What is Loss to Follow-Up (LTFU)?
LTFU happens when someone on HIV treatment misses their medical appointments or stops taking their medication for over 28 days. This is a serious issue, as it can lead to poorer health, increased risk of death, and a higher chance of spreading HIV to others because the virus isn’t being suppressed.
When Do People Stop Treatment?
This study looked at 737 adults who were new to HIV care and identified the times when they were most likely to stop their treatment:
- The First 6 Months Are Critical: About 50% of the people who dropped out of care did so within the first six months. This early period is a high-risk time, with an LTFU rate nine times higher than later periods (13-24 months). People might face challenges like dealing with side effects, struggling to adjust to a new routine, or not yet seeing the benefits of the medication.
- 7-12 Months: A Continued Risk: Even though the risk of dropping out decreases after the first six months, many people still struggle to stick with their treatment during months 7-12. About 30% of those who stopped care did so during this time. Factors like financial difficulties, stigma, or transportation issues can continue to affect them.
- After 12 Months: A More Stable Phase: After a year on treatment, the dropout rate drops significantly. By this time, many patients have adjusted to their routine, seen improvements in their health, and are more committed to their treatment.
What Can We Do About It?
The findings suggest that the first six months of HIV treatment are a make-or-break time. Health programs should focus on providing extra support during this period, such as helping patients manage side effects and offering counseling. Continued support is also important in the following months to help people overcome challenges that might come up later.
Follow the Topic
-
BMC Infectious Diseases
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With Collections, you can get published faster and increase your visibility.
Artificial intelligence in infectious disease management: transforming diagnosis, treatment, and prevention
BMC Infectious Diseases invites submissions for a Collection on Artificial intelligence on infectious disease management.
The advent of artificial intelligence (AI) in healthcare has revolutionized the landscape of infectious disease management. By harnessing the power of machine learning, predictive analytics, and advanced algorithms, AI is poised to transform how we diagnose, treat, and prevent infectious diseases. From rapid identification of pathogens to real-time monitoring of disease outbreaks, AI technologies are increasingly being integrated into public health strategies and clinical practices, offering unprecedented opportunities to enhance patient outcomes and streamline healthcare delivery.
The integration of AI into infectious disease management is crucial for addressing the challenges posed by emerging and re-emerging pathogens, as well as antibiotic resistance. Recent advances in AI-driven diagnostics have shown promise in improving the accuracy and speed of disease detection, while predictive analytics can help forecast outbreaks and inform timely interventions. As these technologies continue to evolve, they hold the potential to significantly enhance our ability to combat infectious diseases on a global scale.
Continued research in this field could lead to groundbreaking developments, such as fully autonomous diagnostic systems that can accurately identify pathogens in real-time, personalized treatment plans tailored to individual patient profiles, and AI systems capable of predicting disease outbreaks before they occur. These advancements could ultimately reshape our approach to infectious disease management, making it more efficient, proactive, and effective.
- AI-driven diagnostics for infectious diseases
- Machine learning applications in healthcare
- Predictive analytics for disease outbreak prediction
- AI in disease prevention strategies
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Dec 31, 2025
Infectious diseases in cancer patients
BMC Infectious Diseases invites submissions for a Collection on Infectious diseases in cancer patients.
Cancer patients are particularly vulnerable to infectious diseases due to their immunocompromised status resulting from both the malignancy itself and the aggressive treatments employed in oncology, such as chemotherapy and radiotherapy. Infections can lead to significant morbidity and mortality in this population, complicating cancer management and adversely affecting treatment outcomes. Understanding the mechanisms behind increased susceptibility to infections in cancer patients is crucial for developing effective preventive measures and therapeutic strategies.
Addressing infectious diseases in cancer patients is vital as recent advances in both cancer treatment and infectious disease management have improved patient survival rates but have also led to a more complex interplay between oncological and infectious complications. Vaccination strategies, the use of prophylactic antibiotics, and advances in infection control practices have shown promise in mitigating risks. Furthermore, the emergence of new pathogens and antibiotic resistance underscores the need for ongoing research in this area to ensure optimal care for this vulnerable population.
With continued research, we may see significant advancements in tailored infection prevention strategies, more effective use of immunotherapies to enhance immune responses in cancer patients, and the development of rapid diagnostic tools for identifying infections. Future studies may also lead to improved understanding of the microbiome's role in cancer patient susceptibility to infections, paving the way for novel therapeutic approaches. We invite submissions that explore a wide array of topics within the scope of infectious diseases, including but not limited to:
- Oncology infections in immunocompromised hosts
- Chemotherapy-associated infections and management
- Infection prevention strategies for cancer patients
- The role of microbiome in cancer-related infections
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.
All manuscripts submitted to this journal, including those submitted to collections and special issues, are assessed in line with our editorial policies and the journal’s peer review process. Reviewers and editors are required to declare competing interests and can be excluded from the peer review process if a competing interest exists.
Publishing Model: Open Access
Deadline: Dec 31, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in